Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Open-labeled Clinical Trial Using a Second-generation Artificial Intelligence-based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy

NCT06050967 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT06050967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06050967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Open-labeled Clinical Trial Using a Second-generation Artificial Intelligence-based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2022
Completion date
March 1, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease type 1